Dose escalation biodistribution, positron emission tomography/computed tomography imaging and dosimetry of a highly specific radionuclide-labeled non-blocking nanobody.

ABSTRACT:

Background

Immunotherapy is a valuable option for cancer treatment, and the curative effect of anti-PD-1/PD-L1 therapy correlates closely with PD-L1 expression levels. Positron emission tomography (PET) imaging of PD-L1 expression is feasible using ⁶⁸Ga-NOTA-Nb109 nanobody. ⁶⁸Ga-NOTA-Nb109 was generated by radionuclide (⁶⁸Ga) labeling of Nb109 using a NOTA chelator. To facilitate clinical trials, we explored the optimal dose range of ⁶⁸Ga-NOTA-Nb109 in BALB/c A375-hPD-L1 tumor-burdened nude mice and C57-hPD-L1 transgenic MC38-hPD-L1 tumor-burdened mice by administration of a single intravenous dose of ⁶⁸Ga-NOTA-Nb109 and confirmed the dose in cynomolgus monkeys. The biodistribution data of cynomolgus monkey PET images were extr

SUBMITTER: Yang Y 

PROVIDER: S-EPMC8557220 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature